Neo Performance Materials (TSX:NEO) Settles European Patent Litigation

TORONTO, Ontario — January 2, 2026 — Leads & Copy — Neo Performance Materials Inc. (TSX: NEO) (OTCQX:NOPMF) announced today that its wholly owned subsidiaries, Neo Chemicals & Oxides (Europe) Ltd., NPM Silmet OÜ and NPM C&O Europe OÜ, have reached a settlement agreement with Rhodia Opérations S.A.S, a Solvay Group subsidiary, to resolve litigation related to European Patents.

The settlement concerns the German designation of European Patents EP 0 735 984 B1, EP 0 605 274 B1, EP 0 863 846 B1, EP 0 955 267 B1, EP 1 527 018 B1, EP 2 007 682 B1, EP 2 523 907 B1, EP 1 435 338 B1 and EP 3 009 403 B1; the Estonian designation is also included in the last patent.

Neo will make a cash payment of €7.1 million to Rhodia in the first quarter of 2026, according to the agreement. All parties have agreed to release claims and withdraw court proceedings related to these patents.

All patents subject to the settlement have expired except for EP ‘682. Neo does not expect the settlement to limit sales of current automotive catalyst products or materially affect earnings because the settlement amount is not materially different from the amount previously accrued by Neo in its financial statements.

Neo manufactures advanced industrial materials, including magnetic powders, rare earth magnets, magnetic assemblies, specialty chemicals, metals and alloys. Neo’s products are used in many everyday products and emerging technologies. The business of Neo is organized along three segments: Magnequench, Chemicals & Oxides and Rare Metals. Neo is headquartered in Toronto, Ontario, with corporate offices in Greenwood Village, Colorado; Singapore; and Beijing, China. Neo has manufacturing facilities in China, Germany, Canada, Estonia, Thailand and the United Kingdom, as well as a research and development center in Singapore.

Source: Neo Performance Materials

×

Welcome!

Biotech Reporter is the source most up-to-date real-time, direct-from-source News Tips and Story Leads.

By Subscribing you will receive Daily Biotech Update each day at 9:30 am ET (Market Open) in your inbox and you can unsubscribe any time.